NASDAQ: EYPT - EyePoint Pharmaceuticals, Inc.

Yield per half year: -45.55%
Dividend yield: 0.00%
Sector: Healthcare

Share chart EyePoint Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About EyePoint Pharmaceuticals, Inc.

Фармацевтическая компания EyePoint Pharmaceuticals, Inc. занимается разработкой и коммерциализацией терапевтических средств для улучшения жизни пациентов с серьезными заболеваниями глаз в США, Китае и Великобритании. Его коммерческие продукты включают YUTIQ для лечения хронического неинфекционного увеита, поражающего задний сегмент глаза; и DEXYCU для лечения послеоперационного воспаления.

more details
В разработке компании используется технология Durasert для устойчивой внутриглазной доставки лекарств, в том числе EYP-1901, экспериментальный интравитреальный препарат с устойчивой доставкой, который находится на второй фазе клинических испытаний. Ранее компания называлась pSivida Corp., а в марте 2018 года сменила название на EyePoint Pharmaceuticals, Inc.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2005-01-27
ISIN US30233G2093
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://eyepointpharma.com
Цена ао 6.06
Change price per day: 0% (5.38)
Change price per week: +16.45% (4.62)
Change price per month: -21.23% (6.83)
Change price per 3 month: -30.58% (7.75)
Change price per half year: -45.55% (9.88)
Change price per year: -74.72% (21.28)
Change price per 3 year: -53.98% (11.69)
Change price per 5 year: +509.91% (0.8821)
Change price per year to date: -23.36% (7.02)
All parameters

Underestimation

Title Value Grade
P/S 19.09 1
P/BV 3.3 5
P/E 0 0
EV/EBITDA -8.23 0
Total: 2

Efficiency

Title Value Grade
ROA, % -19.93 0
ROE, % -26.58 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0747 10
Total: 8.6

Growth impulse

Title Value Grade
Yield Revenue, % 125.58 10
Yield Ebitda, % 55.76 7
Yield EPS, % -68.68 0
Total: 4
More

ETFShare, %Profitability for 1 year, %Dividends, %
Future Tech ETF 0.04656 426.34 0.8416
Principal Healthcare Innovators ETF 0.04656 618.5 0.8416
iShares Morningstar Small-Cap Growth ETF 0.01385 572.1 0.72598
iShares Morningstar Small-Cap ETF 0.00701 391.25 1.60498
0.03502.051



Head Job title Payment Year of birth
Dr. Jay S. Duker M.D. President, CEO & Director 848.5k 1959 (66 years)
Mr. Michael Pine Chief Business Officer 764.85k 1977 (48 years)
Mr. George O. Elston Executive VP & CFO 743.86k 1965 (60 years)
Mr. Ron I. Honig Esq. Chief Legal Officer & Company Secretary N/A
Ms. Jennifer Leonard Chief People Officer & Senior VP of IT N/A
Ms. Isabelle Lefebvre Chief Regulatory Officer N/A
Mr. Michael J. Maciocio Senior Vice President of Manufacturing & Operations N/A
Dr. John B. Landis M.S., Ph.D. Interim Head of R&D and Director 63.75k 1953 (72 years)
Mr. David Scott Jones M.A. Senior VP & Chief Commercial Officer 1967 (58 years)
Dr. Marcia Sellos-Moura Ph.D. Senior VP and Head of Development & Program Management

Address: United States, Watertown. MA, 480 Pleasant Street - open in Google maps, open in Yandex maps
Website: https://eyepointpharma.com